Consensus Alkermes plc

Stocks

ALKS

IE00B56GVS15

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
42.97 ^USD	+4.25%		+6.73%	+53.57%

09-22	Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says	MT
09-21	Alkermes Plc Announces Positive Phase 1b Results Demonstrating Clinical Proof-Of-Concept For ALKS 7290 In Adults With Attention-Deficit Hyperactivity Disorder	CI

Evolution of the Average Target: Alkermes plc

Evolution of the Target Price: Alkermes plc

Changes in Analyst Recommendations: Alkermes plc

198f43be9.6K86VZq-iIvkeQWBKh6-WSsOHAp-EDUEz0a07uBXCZY.ncYJNK_XpdyhQHfzSFz9BltXKnAmVXp-gwj_rLUTS-eQxnEFqNTeu9FMSA~b7f5e40d4749d8e5de930781db6cb708

Analysts' recommendations: Alkermes plc

09-22	Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says	MT
07-29	Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says	MT
06-29	Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says	MT
06-29	BofA Securities Downgrades Alkermes to Underperform From Neutral, $38 Price Target	MT
06-22	Deutsche Bank Lifts Alkermes Price Target to $60 From $47, Maintains Buy Rating	MT
06-09	Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says	MT
06-09	RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating	MT
05-06	Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says	MT
05-06	UBS Adjusts Price Target on Alkermes Public to $48 From $42, Maintains Buy Rating	MT
04-09	BofA Adjusts Price Target on Alkermes Public to $36 From $34, Maintains Neutral Rating	MT
04-07	RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating	MT
02-26	RBC Lowers Price Target on Alkermes to $45 From $47, Keeps Outperform Rating	MT
02-18	Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating	MT
11-19	Alkermes Faces Pressure to Secure the Buyout of Avadel After Lundbeck's Unsolicited Bid, RBC Says	MT
11-17	Truist Raises Price Target on Alkermes to $55 From $50, Keeps Buy Rating	MT
11-13	Deutsche Bank Lowers Price Target on Alkermes to $45 From $55, Keeps Buy Rating	MT
11-11	Truist Initiates Alkermes at Buy With $50 Price Target	MT
25-10-29	Deutsche Bank Adjusts Alkermes Price Target to $55 From $53, Maintains Buy Rating	MT
25-10-23	RBC Raises Price Target on Alkermes to $47 From $45, Keeps Outperform Rating	MT
25-10-08	RBC Lifts Price Target on Alkermes to $45 From $44, Keeps Outperform Rating	MT
25-09-26	Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says	MT
25-09-26	RBC Capital Upgrades Alkermes to Outperform From Sector Perform, Adjusts PT to $44 From $42	MT
25-09-03	Wells Fargo Initiates Alkermes Public at Overweight With $44 Price Target	MT
25-07-30	RBC Raises Price Target on Alkermes to $42 From $40, Keeps Sector Perform Rating	MT
25-06-17	UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALKERMES PLC					+36.37%
	ELI LILLY AND COMPANY					+5.65%
	JOHNSON & JOHNSON					+9.33%
	ABBVIE INC.					-0.99%
	ROCHE HOLDING AG					-0.52%
	MERCK & CO., INC.					+8.56%
	NOVARTIS AG					-0.8%
	ASTRAZENECA PLC					+26.78%
	AMGEN INC.					-8.67%
	GILEAD SCIENCES, INC.					+2.34%
	Average					+7.81%
	Weighted average by Cap.					+5.02%